Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PAQ Therapeutics

Request full access

Pioneering a new approach to restoring health and curing disease through autophagy

Burlington, United StatesFounded 2020Biotech & Life Sciences

About PAQ Therapeutics

PAQ Therapeutics is a pioneering biotechnology startup focused on developing innovative treatments for neurodegenerative diseases. Founded by Dr. Boxun Lu, a globally recognized expert in life sciences and a professor at Fudan University, the company leverages cutting-edge research to address conditions like Huntington's disease, familial ALS, and other polyQ diseases. Dr. Lu's groundbreaking work on ATTEC (Autophagy-Tethering Compounds) forms the scientific backbone of PAQ Therapeutics. This technology aims to harness the body's natural process of autophagy, which is the way cells clean out damaged components, to target and eliminate toxic proteins that cause neurodegenerative diseases.

PAQ Therapeutics operates primarily in the biopharmaceutical market, targeting both academic research institutions and pharmaceutical companies. Their clients include researchers looking for advanced tools to study neurodegeneration and pharmaceutical firms seeking new therapeutic avenues. The company’s business model revolves around the development and licensing of its proprietary ATTEC technology. By partnering with larger pharmaceutical companies, PAQ Therapeutics can co-develop drugs and share in the profits from successful treatments. Additionally, they may receive milestone payments and royalties as their partnered drugs progress through clinical trials and into the market.

Revenue generation for PAQ Therapeutics comes from multiple streams: licensing fees, research grants, and collaborative agreements with pharmaceutical companies. These partnerships not only provide financial support but also accelerate the development and commercialization of their innovative therapies.

In summary, PAQ Therapeutics is at the forefront of biopharmaceutical innovation, focusing on the development of novel treatments for neurodegenerative diseases through its proprietary ATTEC technology. The company serves academic and pharmaceutical clients, operates within the biopharmaceutical market, and generates revenue through licensing, grants, and partnerships.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
77.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2026 $38M $195M Undisclosed ↗
SERIES BOther financing May 2025 $39M $156M Johnson & Johnson Innovation · Sherpa Venture Partners · MRL Ventures · BioTrack Capital ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

PAQ Therapeutics website traffic

Latest recorded traffic for PAQ Therapeutics is 320 monthly website visits, down 17.9% over the last three months. PAQ Therapeutics's team grew 0% over the past year.

Latest monthly visits320 3-month web change-17.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

PAQ Therapeutics in the Burlington ecosystem

Live from Dealroom

The PAQ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A7 investors entered at this stage

  • Sherpa Venture Partners
  • MSA Capital
  • Huagai Capital
  • MRL Ventures
  • Johnson & Johnson Innovation
  • BioTrack Capital
  • LAV

Other known investors1 additional known investor

  • Fudan University
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States87.5%
🇨🇳 China12.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PAQ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PAQ Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.